Views & Analysis

Oncology
antibodies

Antibody drug conjugates – The time is now

The theory behind antibody drug conjugates (ADCs) is simple yet elegant: by combining the specificity of a monoclonal antibody with the cytotoxicity of a potent small molecule drug, ADCs ca

Oncology
ASCO 2023 – Dr Lalan Wilfong

ASCO 2023 – Dr Lalan Wilfong

In the last video from ASCO 2023, we step away from the R&D side to talk about drug costs and payment models.